Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Talphera Inc. (TLPH) Insider Trading Activity
Healthcare • Drug Manufacturers - Specialty & Generic • 15 employees
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
Total Value
$143,880.71
Total Shares
301,781
Average Trade Value
$8,463.57
Most Active Insider
Angotti Vincent J.
Total Activity: $143,329
Largest Single Transaction
$125,000
by Angotti Vincent J. on Apr 2, 2025
30-Day Activity
5 Transactions
Volume: 319,310 shares
Value: $155,000
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Chief Financial Officer
|
Apr 2, 2025 | 15,000 | $10,000 | 47,214 (+31.8%) | Grant | |
|
Chief Medical Officer
|
Apr 2, 2025 | 15,000 | $10,000 | 52,695 (+28.5%) | Grant | |
|
Chief Executive Officer
|
Apr 2, 2025 | 213,310 | $125,000 | 403,769 (+52.8%) | Purchase | |
|
Chief Engineering Officer
|
Apr 2, 2025 | 15,000 | $10,000 | 42,011 (+35.7%) | Grant | |
|
Chief Executive Officer
|
Apr 2, 2025 | 61,000 | $0 | 474,769 (+12.8%) | Grant | |
|
Chief Financial Officer
|
Feb 14, 2025 | 3,245 | $2,174 | 32,214 (-10.1%) | Payment of Exercise Price | |
|
Chief Executive Officer
|
Feb 14, 2025 | 10,575 | $7,085 | 190,459 (-5.6%) | Payment of Exercise Price | |
|
Chief Engineering Officer
|
Feb 14, 2025 | 2,644 | $1,771 | 27,011 (-9.8%) | Payment of Exercise Price | |
|
Chief Engineering Officer
|
Feb 11, 2025 | 880 | $546 | 29,655 (-3.0%) | Payment of Exercise Price | |
|
Chief Financial Officer
|
Feb 11, 2025 | 1,060 | $657 | 35,459 (-3.0%) | Payment of Exercise Price | |
|
Chief Executive Officer
|
Feb 11, 2025 | 3,517 | $2,181 | 201,034 (-1.7%) | Payment of Exercise Price | |
|
Chief Executive Officer
|
Feb 10, 2025 | 3,515 | $2,214 | 204,551 (-1.7%) | Payment of Exercise Price | |
|
Chief Engineering Officer
|
Feb 10, 2025 | 879 | $554 | 30,535 (-2.9%) | Payment of Exercise Price | |
|
Chief Financial Officer
|
Feb 10, 2025 | 1,059 | $667 | 36,519 (-2.9%) | Payment of Exercise Price | |
|
Chief Executive Officer
|
Dec 5, 2024 | 5,000 | $3,200 | 208,066 (+2.4%) | Purchase | |
|
Chief Financial Officer
|
Dec 2, 2024 | 155 | $119 | 37,578 (-0.4%) | Sale | |
|
Chief Executive Officer
|
Nov 27, 2024 | 5,000 | $3,650 | 203,066 (+2.5%) | Purchase |